About Finch Therapeutics
Finch Therapeutics is a company based in Somerville (United States) founded in 2004 by Tom Borody, Zain Kassam, and Jared James Burgess. Finch Therapeutics has raised $184 million across 5 funding rounds from investors including Susquehanna, Octave Group and Symbiosis. The company has 1 employees as of December 31, 2024. Finch Therapeutics offers products and services including Microbiome Assets and IP Estate. Finch Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
- Headquarter Somerville, United States
- Employees 1 as on 31 Dec, 2024
- Founders Tom Borody, Zain Kassam, Jared James Burgess
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Finch Therapeutics Group, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$13.88 M (USD)81.44as on Dec 31, 2024
-
EBITDA
-$18.68 M (USD)42.48as on Dec 31, 2024
-
Total Equity Funding
$184 M (USD)
in 5 rounds
-
Latest Funding Round
$90 M (USD), Series D
Sep 17, 2020
-
Investors
Susquehanna
& 13 more
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Finch Therapeutics
Finch Therapeutics is a publicly listed company on the OTC with ticker symbol FNCH in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Finch Therapeutics
Finch Therapeutics offers a comprehensive portfolio of products and services, including Microbiome Assets and IP Estate.
Portfolio for microbiome-based treatments targeting diseases
Collection of patents for microbiome innovations and applications
People of Finch Therapeutics
Unlock access to complete
Funding Insights of Finch Therapeutics
Finch Therapeutics has successfully raised a total of $184M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $90 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Finch Therapeutics
Finch Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Susquehanna, Octave Group and Symbiosis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Locked | Locked | Locked | |
|
Diversified alternative assets are managed by the investment firm.
|
Locked | Locked | Locked | |
|
Private equity single family office
|
Locked | Locked | Locked |
Investor details for Finch Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Finch Therapeutics
Investment portfolio details for Finch Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Finch Therapeutics
Detailed financials for Finch Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Finch Therapeutics Comparisons
Peer comparison for Finch Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Finch Therapeutics
Finch Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Finch Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Finch Therapeutics
Complete news archive for Finch Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Finch Therapeutics
Finch Therapeutics was founded in 2004 and raised its 1st funding round 11 years after it was founded.
Finch Therapeutics is headquartered in Somerville, United States. It is registered at Somerville, Massachusetts, United States.
Finch Therapeutics is a funded company, having raised a total of $184M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Finch Therapeutics is 1.
Finch Therapeutics was founded in 2004 and is based in Somerville, United States. Microbiome-based therapies are developed using a human-first discovery platform, supported by proprietary machine learning for a clinically annotated library of strains linked to clinical phenotypes. An AquaShell technology is employed for targeted delivery of microbial therapeutics. Focus is placed on Inflammatory Bowel Disease in preclinical stages, along with other applications in the biotechnology sector.
Finch Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Finch Therapeutics offers Microbiome Assets and IP Estate.
Yes, Finch Therapeutics is publicly traded on OTC under the ticker symbol FNCH.
Finch Therapeutics has 14 investors. Key investors include Susquehanna, Octave Group, Symbiosis, OMX Ventures, and MSD Partners.
The ticker symbol of Finch Therapeutics is FNCH on OTC.